Medicine

Latest articles

1. 1. Medicine

   Senescent preosteoclast secretome promotes metabolic syndrome associated osteoarthritis through cyclooxygenase 2

   Weiping Su et al.

   Under metabolic syndrome, joint subchondral preosteoclasts acquire a senescence-associated secretome, which causes a rapid structural alteration of subchondral bone and contributes to the development of osteoarthritis.
2. 1. Computational and Systems Biology
   2. Medicine

   Modeling osteoporosis to design and optimize pharmacological therapies comprising multiple drug types

   David J Jörg et al.

   A mathematical model of osteoporosis explains why the sequence of osteoporosis medications matters for short-term and long-term treatment success.
3. 1. Biochemistry and Chemical Biology
   2. Medicine

   Structure-activity relationships of mitochondria-targeted tetrapeptide pharmacological compounds

   Wayne Mitchell et al.

   Sequence-variant analogs of mitochondria-targeted tetrapeptides have distinct patterns of membrane-bound conformations, effects on membrane properties, and abilities to protect mitochondria subject to stress, illuminating how side chain variation can be leveraged in the development of more effective therapeutic compounds.
4. 1. Medicine

   Evolution of multiple omics approaches to define pathophysiology of pediatric acute respiratory distress syndrome

   Jane E Whitney et al.

   Multiple -omics approaches have provided valuable insight into the pathobiology of pediatric acute respiratory distress syndrome, and novel unbiased techniques hold promise for future discoveries.
5. 1. Medicine

   Microscopic colitis: Etiopathology, diagnosis, and rational management

   Ole Haagen Nielsen et al.

   State-of-the-art knowledge of microscopic colitis, a disease often more prevalent than ulcerative colitis and Crohn’s disease among elderly people, is provided from a global perspective with the overall aim to create better awareness and improve rational management.
6. 1. Immunology and Inflammation
   2. Medicine

   Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273

   Niels JM Verstegen et al.

   SARS-CoV-2 experienced ocrelizumab-treated MS patients benefit from SARS-CoV-2 mRNA vaccination by inducing broadprotective CD8+ T-cells, whereas methotrexate-treated RA patients induce delayed but strong antibody responses, which support vaccine strategies for these patient groups.
7. 1. Medicine
   2. Microbiology and Infectious Disease

   Reconstruction of transmission chains of SARS-CoV-2 amidst multiple outbreaks in a geriatric acute-care hospital: a combined retrospective epidemiological and genomic study

   Mohamed Abbas et al.

   Nosocomial transmission of SARS-Cov-2 in geriatric settings is complex, with different patterns between patients and healthcare workers working in Covid/non-Covid wards that should be taken into account when designing infection control strategies.
8. 1. Medicine

   Insights from full-text analyses of the Journal of the American Medical Association and the New England Journal of Medicine

   Moustafa Abdalla et al.

   Historical analysis of nearly half-a-million articles from the Journal of the American Medical Association and the New England Journal of Medicine since their inception frames the shifting scientific, material, ethical, and epistemic underpinnings of medicine over time, including today.
9. 1. Genetics and Genomics
   2. Medicine

   Unbiased mosaic variant assessment in sperm: a cohort study to test predictability of transmission

   Martin W Breuss et al.

   The abundance of mosaic variants detected directly in sperm accurately predicts their transmission to concepti.
10. 1. Medicine

    Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trial

    Montaser F Shaheen et al.

    Pathogenic activating mutations in PIK3CA or NRAS were the most common genetic findings in a lymphatic malformation patient cohort and an N-of-1 trial of the PI3Kα inhibitor alpelisib in a patient with a PIK3CA mutation confirmed these findings are actionable.